New covid-19 treatments are here, but who gets them?
Inequality and poor planning have marred the U.S. response to Covid-19. The same can't happen for new therapies like the one just approved from Eli Lilly.
When it rains good pandemic news, it pours. On a Monday that brought unexpectedly positive vaccine news from Pfizer Inc. and BioNTech SE, the Food and Drug Administration also granted emergency use authorization to an Eli Lilly & Co. drug to treatment for individuals newly infected with the coronavirus. It's the first to be approved of a promising group of therapies called monoclonal antibodies that mimic the body’s response to infection, and could be a powerful weapon in the pandemic fight.